Background/Aims: The epigenetic factor KDM2B is a histone demethylase expressed in various tumors. Recently, we have shown that KDM2B regulates actin cytoskeleton organization, small Rho GTPases signaling, cell-cell adhesion and migration of prostate tumor cells. In the present study, we addressed its role in regulating EMT and small GTPases expression in colon tumor cells. Methods: We used RT-PCR for the transcriptional analysis of various genes, Western blotting for the assessment of protein expression and immunofluorescence microscopy for visualization of fluorescently labeled proteins. Results: We report here that KDM2B regulates EZH2 and BMI1 in HCT116 colon tumor cells. Knockdown of this epigenetic factor induced potent up-regulation of the protein levels of the epithelial markers E-cadherin and ZO-1, while the mesenchymal marker N-cadherin was downregulated. On the other hand, KDM2B overexpression downregulated the levels of both epithelial markers and upregulated the mesenchymal marker, suggesting control of EMT by KDM2B. In addition, RhoA, RhoB and RhoC protein levels diminished upon KDM2B-knockdown, while all three small GTPases became upregulated in KDM2B-overexpressing HCT116 cell clones. Interestingly, Rac1 GTPase level increased upon KDM2B-knockdown and diminished in KDM2B-overexpressing HCT116 colon tumor-and DU-145 prostate cancer cells. Conclusions: These results establish a clear functional role of the epigenetic factor KDM2B in the regulation of EMT and small-GTPases expression in colon tumor cells and further support the recently postulated oncogenic role of this histone demethylase in various tumors.
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Introduction
The epigenetic factor KDM2B is a novel oncogene, coding for a lysine-specific demethylase that removes H3K4me3 and H3K36me2 histone marks from the histones leading to transcriptional repression [1] [2] [3] [4] . The function of KDM2B depends on the co-operation with Polycomb Repressor Complex-2 (PRC-2) that enables MEFs to undergo immortalization [4] . KDM2B is regulated by the basic fibroblast growth factor (bFGF) in human tumors that in turn governs various tumor characteristics including cell growth, migration, invasiveness, angiogenesis and actin cytoskeleton organization [5] [6] [7] . A previous study reported control of cell migration and angiogenesis by KDM2B in HUVECs [6] . In line with this report, recent studies from our group in DU-145 prostate cancer cells established a significant role of this epigenetic factor in regulating cell migration [8] . Analysis of the underling mechanism revealed the involvement of actin cytoskeleton reorganization, Rho GTPase signaling and cell-cell adhesion molecules E-cadherin and ZO-1 [8] . These findings supported previous reports suggesting that epigenetic mechanisms regulate actin cytoskeleton architecture [8] [9] [10] that in turn is a crucial mediator conferring cancer cells with migratory and invasive characteristics [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . In addition, these studies established a clear link between KDM2B function, actin architecture and migration in prostate cancer cells [8] . However, it remained unclear whether the control of actin cytoskeleton signaling mechanisms, including activity of Rho GTPases, by this epigenetic factor is a general regulatory phenomenon, relevant for other tumor cells and whether KDM2B-induced cell-cell adhesion alterations may as well influence epithelial to mesenchymal transition (EMT). To this end, in the present study we addressed whether epigenetic alterations result in the deregulation of small GTPases function and may influence EMT in colon tumor cells. For this, we analyzed whether KDM2B governs the expression of small GTPases genes, including RhoA/RhoB/RhoC and Rac1, and addressed its role in regulating the EMT markers E-cadherin, N-cadherin and ZO-1 in HCT116 colon cancer cells. Our findings fully support the notion that in tumor cells, epigenetic mechanisms control the expression and function of EMT and cytoskeletal genes.
Materials and Methods
RPMI 1640 medium, penicillin/streptomycin, trypsin, puromycin, SuperScript II Reverse Transcriptase, Trizol reagent for RNA extraction, dNTPs, ProLong Gold Antifade reagent with Dapi and Anti-Zo1 (339100) were purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA). Fetal Bovine Serum (FBS) was purchased from Biochrom (Berlin, Germany), RT-PCR primers from Eurofins MWG Operon (Ebersberg, Germany). FITC-IgG antibody was from Molecular probes Inc (Eugene OR USA). Anti-Ezh2 (D2C9), anti-Bmi1 (D20B7), anti-N-Cadherin (13A9) and anti-RhoC (D40E4) antibodies were from Cell Signaling Technology (Danvers, MA, USA). Anti-RhoA (sc-418), anti-RhoB (sc-180) and anti-Rac1 (sc-95) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and KAPA SYBR Green/ROX qPCR Master Mix from Fermentas (Maryland, USA). Anti-JHDM1B (KDM2B) (09-864) antibody, Goat anti-rabbit and anti-mouse IgG Peroxidase Conjugated antibodies and ECL Immobilon western-Chemiluminescent HRP Substrate were purchased from Millipore Corporation (Billerica, MA, USA). Albumin Fraction V (BSA) was from PanReac Applichem, ITW Reagents (Gatersleben, Germany). All other chemicals were from usual commercial sources at the purest grade available.
Cell cultures, Lentiviral and Retroviral packaging and transduction
HCT116 and DU-145 cell lines were cultured in RPMI 1640, supplemented with 1% penicillin/ streptomycin and 10% heat-inactivated fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37°C. Lentiviral and retroviral packaging and transduction in HCT116 cells were performed as described previously [8] . Cells infected with retrovirus ((pBABEpuro-KDM2B (for overexpression KDM2B) or control empty vector pBABEpuro (control for overexpressing KDM2B cells)) or lentivirus (pLKO.1KDM2BshRNA (expressing either shKDM2B (pLKO.1-KDM2B-sh) or scramble shRNA (pLKO.1-scrambled-sh)) constructs. Lentiviral-based shRNAs for human KDM2B were purchased from Open Biosystems (cat no. RH54533- 
Protein extraction and Western Blotting
For Western blotting, lentiviral or retroviral transduced cells were lysed in lysis buffer: (Tris-HCl 50mM pH7.5, NaCl 150mM, Triton X-100 1%, SDS 0, 2% and sodium deoxycholate 0, 1%, Protease/Phosphatase inhibitor cocktail of NaF 1M, Leupeptin 1M, β-glycerophosphate 10mM, Na3VO4 10mM, Aprotinin 80μM, Pepstatin A 1mM, E-64 1, 5mM, Bestatin 5mM, AEBSF 100mM). Total protein extracts were analyzed by Western blotting followed by nitrocellulose membrane blotting with specific antibodies, as previously described [8] . Protein band intensity was quantified by using Image Lab Software (Bio-Rad).
RNA isolation, cDNA synthesis and Real time PCR
The cell lysates were processed for total RNA extraction using Trizol reagent according to the manufacturer's instructions. cDNA synthesis and real time PCR were performed as described previously [8] . For the amplification the following primers were used (5'-3' orientation):
Actin, forward CGGCATCGTCACCAACTG; Actin, reverse GGCACACGCAGCTCATTG; Kdm2b, forward TCTACGAGATCGAGGACAGGA; Kdm2b, reverse ACCAGCACATCTCATAGTAGAAGG .
Immunofluorescence
Immunofluorescence microscopy experiments in HCT116 cells were performed as described previously [8] . Primary antibodies used were anti-JHDM1B (KDM2B) (1:100, 09-864, Millipore), anti-EZH2 (1:100, D2C9, Cell Signaling Technology) and anti-BMI 1 (1:100, D20B7, Cell Signaling Technology), and secondary antibodies Alexa 555-conjugated goat (1:600, anti-rabbit, Invitrogen) and FITC 488 (1:500, anti-mouse, Invitrogen). The slides were mounted using the ProLong Gold Antifade reagent with Dapi. Photomicrographs were obtained with a LEICA microscope (LEICA DM LB) and were photographed with a LEICA DC 300F digital camera, using the Zeiss Plan-neofluar 40×/0.75 objective lens. The images were analyzed with the instrument's software.
Replicates and Statistical Analysis
All experiments were performed in 3 independent replications and data are presented as means ± standard deviation (SD). All data were tested for significance using unpaired Student t-test, with P values of 0.05 or less being considered statistically significant (* (p<0.05), ** (p<0.01), *** (p<0.001)).
Results
In line with previous reports [8] , expression of KDM2B protein was evident in HCT116 colon tumor cells (Fig. 1A) . Compared to scramble shRNA, knockdown of KDM2B revealed downregulation of both, gene transcripts (Fig. 1B, left panel) and protein levels (Fig. 1C, left  panels) . On the other hand, overexpression of KDM2B bare up-regulation of gene transcripts (Fig. 1B, right panel) and protein levels (Fig. 1C, right panels) . These findings were fully supported by IF microscopic analysis (Fig. 1D) .
KDM2B gene was functional in HCT116 cells, since knockdown resulted in clear reduction of EZH2 protein levels ( Fig. 2A, left panels) , whereas overexpression induced enhanced EZH2 expression ( Fig. 2A, right panel) . In addition to EZH2, KDM2B regulated as well BMI1 protein levels in HCT116 cells (Fig. 2B) . IF microscopic observations ( Fig. 2C and D) strengthened these findings.
We further analyzed the role of KDM2B in controlling EMT in tumor cells by assessing the expression profiles of the EMT markers E-Cadherin, ZO-1 and N-Cadherin. Knockdown of KDM2B gene in HCT116 cell clones revealed elevated protein expression of the epithelial Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry 
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Cellular Physiology and Biochemistry marker E-Cadherin (Fig. 3A , left panels), while cell clones overexpressing KDM2B showed reduced E-Cadherin protein levels (Fig. 3A, right panels) . These findings are in line with recently reported regulation of E-Cadherin gene transcription by KDM2B in DU-145 cells [8] . Very similar results were obtained for an additional epithelial marker, namely ZO-1 (Fig.  3B) . Finally, we assessed the expression profile of the mesenchymal marker N-Cadherin. Interestingly, shRNA-mediated knockdown of KDM2B in HCT116 cell clones revealed potent downregulation of protein expression (Fig. 3C , left panels), while cell clones overexpressing KDM2B showed enhanced N-Cadherin protein levels (Fig. 3C, right panels) . These results suggest that the epigenetic factor KDM2B regulates EMT in HCT116 colon tumor cells. In our recent study [8] , we demonstrated a clear correlation between KDM2B function, actin organization and small GTPases signaling in prostate cancer cells. Moreover, previous reports established a functional link between EMT, actin cytoskeleton reorganization and small GTPases signaling [20] [21] [22] [23] [24] [25] [26] [27] . Accordingly, we further analyzed the functional link of the KDM2B gene with various small GTPase family proteins, namely RhoA/B/C and Rac1 in colon tumor cells. Knockdown of KDM2B in HCT116 cell clones revealed a clear decrease of RhoA, RhoB and RhoC protein levels as manifested by Western blotting (Fig. 4A , B, C, left panels), while overexpression of KDM2B exhibited enhanced protein levels of all tested small GTPases (Fig. 4A, B, C, right panels) . Interestingly, the opposite effect was evident for Rac1. As shown in Fig. 5A , clear upregulation of the Rac1 small GTPase protein expression became evident upon knockdown of KDM2B in HCT116 cell clones (Fig. 5A, left panels) , while KDM2B overexpression induced downregulation of Rac1 protein level (Fig. 5A, right  panels) . We further investigated whether this finding was evident as well in other tumor cells upon KDM2B knockdown or overexpression. We observed very similar results in DU-145 prostate cancer cells, since knockdown or overexpression respectively of KDM2B in these cells revealed clear enhanced (Fig. 5B left panel) or diminished (Fig. 5B right panel) Rac1 protein expression.
Discussion
In this study, we addressed the regulatory role of the epigenetic factor KDM2B by analyzing EMT and Rho GTPases in HCT116 colon tumor cells. Our results established that KDM2B overexpression or knockdown regulates: a) the expression profiles of EZH2 and BMI1, b) the expression levels of the epithelial markers E-Cadherin and ZO-1, as well as the mesenchymal marker N-Cadherin, c) the protein levels of RhoA, RhoB and RhoC small GTPases and finally, d) the protein levels of Rac1 small GTPase. These results imply that this epigenetic factor controls EMT and small Rho GTPase expression in HCT116 colon cancer cells and is in line with previously reported findings in prostate cancer cells [8] . Taking together, these results argue that KDM2B has a significant oncogenic role in regulating cell functions in various tumors. Previous work showed that the upregulation of KDM2B in co-operation with Polycomb group proteins promotes motility and invasion in tumor cell lines and primary tumors [5, 6] . In line with these reports, in a recent study from our group we elucidated a novel signaling pathway that is regulating KDM2B-induced migration in prostate tumor cells [8] . This mechanism involved the small GTPases RhoA and RhoB, the epithelial markers E-Cadherin and ZO-1 as well as deregulation of actin cytoskeleton organization, which in turn controlled the migration of prostate tumor cells [8] . Interestingly, as previously reported, a migration assay failed to establish a clear relationship between KDM2B expression and motility in HCT116 colon tumor cells [8] . Since KDM2B protein levels in HCT116 cells are significantly lower compared to DU-145 prostate cancer cells ( [8] , and Fig. 1A ), this observation suggests that variable basal KDM2B expression levels may differentially regulate the migratory behavior of tumor cells and needs further investigation.
Our data establish also a clear involvement of epigenetic factors in controlling EMT. This became evident from the opposite effects on the expression of the epithelial markers E-Cadherin and ZO-1 versus the mesenchymal marker N-Cadherin, shown upon knockdown or overexpression of the KDM2B gene. This observation implies a significant role of KDM2B in tumorigenesis and suggests the implication of actin cytoskeleton and small GTPases signaling in this phenomenon. Indeed, this assumption was postulated previously in various tumor cell models by analyzing the correlation of EMT with actin signaling and migration [13, [19] [20] [21] [22] [23] [24] [25] [26] [27] . Moreover, previous studies showed that the Serum glucocorticoid kinase 1 (Sgk1) plays a key role in EMT in colon carcinoma [28] . Furthermore, Sgk1 regulates epigenomic re-alignment and drug-resistance through the control of GTP-proteins RANBP1 and RAN [29] . Accordingly, co-regulation between KDM2B and Sgk1 seems possible and needs further investigation.
Regulation of Rho small GTPases function is a crucial step in the oncogenic behavior of various tumor cells, including growth, migration and apoptosis [11, 15, 16, 18, 30, 31] . Rho signaling governs actin redistribution [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] and is implicated in various cellular responses including cell-cell adhesion and EMT [13, 22, 25, [42] [43] [44] [45] . In the present work, we reported opposite effects of the KDM2B gene in the expression of RhoA/RhoB/RhoC-and Rac1-GTPases. This is an interesting observation that needs further analysis. However, since Rho GTPases are implicated in the formation of actin stress fibers [46, 47] , while Rac1 promotes restructuring of actin cytoskeleton towards lamelipodia [47] [48] [49] [50] our findings may indicate that the epigenetic factor KDM2B plays a differential role in actin reorganization. This may include promotion of lamelipodia formation with concomitant inhibition of stress fibers and vice versa. Such a mechanism may be crucial for controlling simultaneously both, growth and motility of tumor cells [48, [51] [52] [53] . In addition, since KDM2B governed Rac1 regulation was as well evident in DU-145 prostate cancer cells (Fig. 5B) , we assume that this regulatory step may as well contribute to the reported control of cell migration of prostate cancer cells [8] , as previously described in breast cancer cells [54] . On the other hand, regulation of Rac1 GTPase expression in HCT116 cell may be correlated with the control of tumor cells invasion from the intestine epithelium into the endothelium of blood vessels through the formation of lamelipodia, rather than controlling the migration in wound healing experiments in a flat substrate such as cell culture flask. Additional work is now needed to address these interesting issues.
To conclude, in the present work we demonstrate that the histone demethylase KDM2B is regulating the expression of EMT markers E-Cadherin, ZO-1 and N-Cadherin and the small GTPases RhoA/B/C and Rac1 in colon tumor cells. Taking into consideration the recently Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
